- Clone:
- REA409 | RV202
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- ICFC, MICS, 3D-IF, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for Vimentin Antibody, anti-human, REAfinity™
Clone REA409 recognizes the human vimentin antigen, a 57 kDa molecule which is one of the most widely expressed and highly conserved proteins of the type III intermediate filament (IF) protein family. Vimentin is expressed in a wide range of cell types, including pancreatic precursor cells, sertoli cells, neuronal precursor cells, trophoblastic giant cells, fibroblasts, endothelial cells lining blood vessels, renal tubular cells, macrophages, neutrophils, mesangial cells, leukocytes, and renal stromal cells. Increased vimentin expression has been reported in various epithelial cancers including prostate cancer, gastrointestinal tumors, CNS tumors, breast cancer, malignant melanoma, lung cancer, and other types of cancers. Vimentin's over-expression in cancer correlates well with increased tumor growth, invasion, and poor prognosis. Vimentin has gained much importance as a canonical marker of epithelial-mesenchymal transition (EMT), a cellular re-programming process in which the epithelial cells acquire a mesenchymal phenotype that renders the cells to dramatically alter their shape and exhibit increased motility. This EMT is characterized by the expression of vimentin IFs in epithelial cells, which normally express only keratin IFs. Accordingly, during the reverse process of EMT, known as mesenchymal-epithelial transition (MET), the cells start acquiring epithelial phenotype and show a decreased vimentin expression with lower motility rates.
Additional information: Clone REA409 displays negligible binding to Fc receptors.
VIM, CTRCT30, HEL113
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.